Salute e Benessere
Crossject reports audited financial results for 2023
Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free auto-injectors technology platform ZENEO®, reports its audited financial results for the year ending December 31, 2023. These results are now available on the Company's website.
Key financial information as of December 31, 2023
Crossject's financial results for the year ending December 31, 2023 have now been fully audited with a minor change of -0.17 M€ compared to the previous report, released on March 29 and available here .
All reports relating to financials for the year 2023 will be available on the Crossject website from April 30 and are also presented in the appendices below.
The table below summarizes our income statement for the years ending 31 December 2023 and 2022:
About Crossject
Crossject SA (Euronext: ALCJ; www.crossject.com ) is an emerging specialty pharma company developing products for emergencies harnessing its proprietary needle-free auto-injector technology ZENEO. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company's award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company's other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.
For further information, please contact:
APPENDICES
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti